Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial
Year: 2025
Type: article
Abstract: BACKGROUND AND OBJECTIVE: The aim of this study was to evaluate the prognostic value of undetectable circulating tumor DNA (ctDNA) and the dose-response relationship between ctDNA levels and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC). METHODS: We analyzed data for patients enrolled in the ProBio trial up to November 2022 who received an androgen receptor pathway inhibitor or taxane. We compared survival outcomes between patients with undetectable ctDNA and those with detectable ctDNA randomized to physician's choice or investigational arms. Time to no longer clinically benefiting (NLCB) and overall survival (OS) were assessed using Bayesian survival models, with results reported as survival time ratios (STRs). Dose-response relationships were estimated using spike-at-zero models. KEY FINDINGS AND LIMITATIONS: A total of 220 patients were included, of whom 139 had detectable ctDNA (56 in the physician's choice arm, 83 in investigational arms) and 81 had undetectable ctDNA. In comparison to the undetectable ctDNA group, the physician's choice arm had 60% shorter time to NLCB (STR 0.40, 90% credible interval [CrI] 0.31-0.51) and 51% shorter OS (STR 0.49, 90% CrI 0.38-0.61). Similar results were observed in comparison to the investigational arms. Dose-response analysis revealed that the undetectable ctDNA group had twofold longer time to NLCB (STR 2.05, 90% CrI 1.66-2.57) and 1.6-fold longer OS (STR 1.63, 90% CrI 1.33-2.05) in comparison to the subgroup with a ctDNA fraction of 2.5%. Every 10-point increment in the ctDNA fraction corresponded to a 10% reduction in NLCB and OS times. CONCLUSIONS AND CLINICAL IMPLICATIONS: Undetectable ctDNA at baseline predicts superior prognosis in mCRPC, suggesting potential for treatment de-escalation and less intensive monitoring for this subgroup of patients. This trial is registered on ClinicalTrials.gov as NCT03903835.
Source: European Urology Oncology
Authors: Alessio Crippa, Bram De Laere, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D’hondt, Marie Hjälm-Eriksson, Linn Pettersson, Gunilla Enblad, Anders Ullén, Nicolaas Lumen, Camilla Thellenberg Karlsson, Johan Sandzén, Elin Jänes, Christophe Ghysel, Martha Olsson, Brieuc Sautois, Peter Schatteman, Wendy De Roock, Siska Van Bruwaene, Ingrida Verbiene, Jochen Darras, Els Everaert, Daan De Maeseneer, Mats Anden, Michiel Strijbos, Daisy Luyten, Ashkan Mortezavi, Jan Oldenburg, Piet Ost, Johan Lindberg, Henrik Grönberg, Martin Eklund
Institutions: Karolinska Institutet, Ghent University, Ghent University Hospital, Saint Göran Hospital, Ryhov Hospital Jönköping, Uppsala University Hospital, Karolinska University Hospital, University Hospital of Umeå, Karlstad Central Hospital, Sundsvall Municipality, AZ Sint-Jan, Centrallasarettet Växjö, Centre Hospitalier Universitaire de Liège, Onze Lieve Vrouwziekenhuis Hospital, Ziekenhuis Oost-Limburg, AZ Groeninge, Falun Hospital, Damiaan Dicht bij het leven, AZ Sint-Lucas, AZ Sint-Lucas, Länssjukhuset i Kalmar, Landstinget i Kalmar län, GZA Ziekenhuizen Campus Sint-Augustinus, GZA Ziekenhuizen, Jessa Hospital, University Hospital of Basel, University Hospital Zurich, Akershus University Hospital, Science for Life Laboratory
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,790
OpenAlex ID: W4409640070